Inventor · disambiguated record
John Puisis
Also filed as: PUISIS JOHN · PUISIS JOHN J
6 granted patents·11 pending applications·18 citations·filing 2012–2023
78Inventor score
Top patents by PatentIndex Score
17 records- 0187US8722049B2Antibody and methods for selective inhibition of T-cell responsesTOLERA THERAPEUTICS INC·Filed 2013·Granted May 13, 2014·6 cites·7 claims
- 0286US11510996B2Covalent polymer-antigen conjugated particlesCOUR PHARMACEUTICALS DEV COMPANY INC·Filed 2016·Granted Nov 29, 2022·3 cites·18 claims
- 0384US8524234B2Antibody for selective inhibition of T-cell responsesTOLERA THERAPEUTICS INC·Filed 2012·Granted Sep 3, 2013·8 cites·2 claims
- 0480US11045492B2Immune-modifying nanoparticles for the treatment of inflammatory diseasesONCOUR PHARMA INC·Filed 2018·Granted Jun 29, 2021·1 cites·28 claims
- 0573US12502436B2Covalent polymer-antigen conjugated particlesCOUR PHARMACEUTICALS DEV COMPANY INC·Filed 2022·Granted Dec 23, 2025·0 cites·20 claims
- 0657US8968739B2Antibody and methods for selective inhibition of T-cell responsesTOLERA THERAPEUTICS INC·Filed 2013·Granted Mar 3, 2015·0 cites·6 claims
- 0757US2025367274A1Tolerizing Immune Modifying Nanoparticles for Overcoming the Immunogenicity of Therapeutic Vectors and ProteinsCOUR PHARMACEUTICALS DEV COMPANY INC·Filed 2023·Application pending·0 cites
- 0855US2013273089A1Antibody and methods for selective inhibition of t-cell responsesTOLERA THERAPEUTICS INC·Filed 2013·Application pending·0 cites
- 0952US2025319155A1Preparation of tolerizing nanoparticles for the treatment of peanut allergyCOUR PHARMACEUTICALS DEV COMPANY INC·Filed 2022·Application pending·0 cites
- 1051US2024197866A1Treatment of peanut allergy with tolerizing nanoparticlesCOUR PHARMACEUTICALS DEV COMPANY INC·Filed 2022·Application pending·0 cites
- 1151US2024408186A1Treatment of primary biliary cholangitis (pbc) with tolerizing nanoparticlesCOUR PHARMACEUTICALS DEV COMPANY INC·Filed 2022·Application pending·0 cites
- 1250US2024201187A1Method of Tracking Maintenance of Immunological ToleranceCOUR PHARMACEUTICALS DEV COMPANY INC·Filed 2022·Application pending·0 cites
- 1350US2023190895A1Negatively charged particles for the treatment of cytokine storm syndrome (css) and acute respiratory distress syndrome (ards)ONCOUR PHARMA INC·Filed 2021·Application pending·0 cites
- 1450US2025170066A1Treatment of solid tumors with negatively charged particlesONCOUR PHARMA INC·Filed 2023·Application pending·0 cites
- 1547US2021290661A1Immune modifying particles for the treatment of cancerONCOUR PHARMA INC·Filed 2019·Application pending·0 cites
- 1643US2015252109A1Antibody and methods for selective inhibition of t-cell responsesTOLERA THERAPEUTICS INC·Filed 2015·Application pending·0 cites
- 1741US2022257768A1Treatment of immune evasive tumorsONCOUR PHARMA INC·Filed 2020·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →